Table of contents

Extended reports

• Phenotypic and functional characterisation of ovine mesenchymal stem cells: application to a cartilage defect model (20 July, 2007)

  D Mrugala, C Bony, N Neves, L Caillot, S Fabre, D Moukoko, C Jorgensen, D Noël
• The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis (29 October, 2007)

  A P Anandarajah, E M Schwarz, S Totterman, J Monu, C Y Feng, T Shao, S A Haas-Smith, C T Ritchlin
• Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France (18 October, 2007) Free

  T Lequerré, P Quartier, D Rosellini, F Alaoui, M De Bandt, O Mejjad, I Kone-Paut, M Michel, E Dernis, M Khellaf, N Limal, C Job-Deslandre, B Fautrel, X Le Loët, J Sibilia, on behalf of the Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP) and the Club Rhumatismes et Inflammation (CRI)
• Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis (17 September, 2007)

  A Céspedes-Cruz, R Gutiérrez-Suárez, A Pistorio, A Ravelli, A Loy, K J Murray, V Gerloni, N Wulffraat, S Oliveira, J Walsh, I Calvo Penades, M G Alpigiani, P Lahdenne, C Saad-Magalhães, E Cortis, L Lepore, Y Kimura, C Wouters, A Martini, N Ruperto, for the Pediatric Rheumatology International Trials Organization (PRINTO)
• Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II) (27 October, 2007)

  K Krueger, L Lino, R Dore, S Radominski, Y Zhang, A Kaur, R Simpson, S Curtis
• Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study (6 July, 2007) Free

  J Sieper, T Klopsch, M Richter, A Kapelle, M Rudwaleit, S Schwank, E Regourd, M May
• Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response (7 September, 2007)

  T Jónsdóttir, I Gunnarsson, A Risselada, E W Henriksson, L Klareskog, R F van Vollenhoven
• Effects of strontium ranelate on spinal osteoarthritis progression (26 October, 2007)

  O Bruyere, D Delferriere, C Roux, J D Wark, T Spector, J-P Devogelaer, K Brixen, S Adami, J Fechtenbaum, S Kolta, J-Y Reginster
• Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response (29 October, 2007)

  J Braun, X Baraliakos, J Listing, C Fritz, R Alten, G Burmester, A Krause, S Schewe, M Schneider, H Sörensen, H Zeidler, J Sieper
• Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis (29 October, 2007)

  J C Davis, D M van der Heijde, J Braun, M Dougados, D O Clegg, A J Kivitz, R M Fleischmann, R D Inman, L Ni, S-L Lin, W H Tsuji
• Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis (20 July, 2007)

  F Chopin, P Garnero, A le Henanff, F Debiais, A Daragon, C Roux, J Sany, D Wendling, C Zarnitsky, P Ravaud, T Thomas
• Associations between Human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study (31 July, 2007)

  E W Karlson, L B Chibnik, J Cui, R M Plenge, R J Glass, N E Maher, A Parker, R Roubenoff, E Izmailova, J S Coblyn, M E Weinblatt, N A Shadick
• Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register (20 July, 2007)

  L E Kristensen, A Gülfe, T Saxne, P Geborek
• The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis (27 July, 2007)

  M Bartoli, M Tarò, S Magni-Manzoni, A Pistorio, F Traverso, S Viola, A Magnani, C Gasparini, A Martini, A Ravelli
• Reliability and sensitivity to change of the Simple Erosion Narrowing Score compared with the Sharp–van der Heijde method for scoring radiographs in rheumatoid arthritis (20 July, 2007)

  E M Dias, C Lukas, R Landewé, S Fatenejad, D van der Heijde
• Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis (27 July, 2007)

  S Tsujimura, K Saito, M Nawata, S Nakayamada, Y Tanaka
• Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts (27 July, 2007)

  L C Huber, P Künzler, S H Boyce, B A Michel, R E Gay, B S Ink, S Gay
• Anti-heparin platelet factor 4 antibodies in systemic lupus erythaematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome (20 July, 2007)

  D Alpert, L A Mandl, D Erkan, W Yin, E I Peerschke, J E Salmon
• Assessment of rituximab’s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results (20 July, 2007)

  A Kavanaugh, S Rosengren, S J Lee, D Hammaker, G S Firestein, K Kalunian, N Wei, D L Boyle
• Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis (29 June, 2007)

  C McKinney, M E Merriman, P T Chapman, P J Gow, A A Harrison, J Highton, P B B Jones, L McLean, J L O’Donnell, V Pokorny, M Spellerberg, L K Stamp, J Willis, S Steer, T R Merriman